Privium Fund Management B.V. Has $144,000 Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Privium Fund Management B.V. increased its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) by 74.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,000 shares of the biopharmaceutical company’s stock after buying an additional 37,000 shares during the period. Privium Fund Management B.V. owned 0.08% of Fate Therapeutics worth $144,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Intech Investment Management LLC grew its stake in Fate Therapeutics by 27.5% in the 4th quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 8,497 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Fate Therapeutics by 30.6% during the fourth quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 10,511 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Fate Therapeutics by 0.5% during the third quarter. Geode Capital Management LLC now owns 2,258,246 shares of the biopharmaceutical company’s stock worth $7,905,000 after acquiring an additional 10,863 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Fate Therapeutics in the fourth quarter valued at approximately $40,000. Finally, Thrivent Financial for Lutherans increased its stake in shares of Fate Therapeutics by 24.7% during the third quarter. Thrivent Financial for Lutherans now owns 125,370 shares of the biopharmaceutical company’s stock worth $439,000 after purchasing an additional 24,804 shares during the period. 97.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. StockNews.com downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 11th. Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a research note on Thursday, March 6th. Stifel Nicolaus dropped their price objective on shares of Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Thursday, March 6th. Wedbush restated a “neutral” rating and set a $5.00 target price on shares of Fate Therapeutics in a research report on Thursday, March 6th. Finally, Wells Fargo & Company lowered their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Fate Therapeutics has an average rating of “Hold” and a consensus target price of $5.50.

Fate Therapeutics Trading Down 4.7 %

NASDAQ FATE opened at $0.92 on Wednesday. The firm’s 50 day simple moving average is $1.25 and its 200 day simple moving average is $2.22. The firm has a market capitalization of $105.49 million, a price-to-earnings ratio of -0.56 and a beta of 2.26. Fate Therapeutics, Inc. has a 1 year low of $0.87 and a 1 year high of $7.70.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.13. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The firm had revenue of $1.86 million for the quarter, compared to the consensus estimate of $1.57 million. On average, equities research analysts forecast that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Insider Buying and Selling at Fate Therapeutics

In related news, Director Redmile Group, Llc purchased 397,964 shares of Fate Therapeutics stock in a transaction dated Friday, December 20th. The shares were bought at an average cost of $1.68 per share, for a total transaction of $668,579.52. Following the purchase, the director now owns 12,884,277 shares in the company, valued at approximately $21,645,585.36. This trade represents a 3.19 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.00% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.